Impact Assessment for Regulations under the Health Act 2009: Control of Entry and Exit in the NHS Pharmaceutical Market (IA 5035)

To ensure a proportionate regulatory regime which encourages the supply of NHS pharmaceutical services without excessive provision in areas already adequately meeting demand, to ensure the benefits of new entry outweigh costs and to align provision more transparently with local needs.

DH 5035 Market entry and exit (PDF 216K)

Equality Analysis (PDF 108K)

RPC Opinion DH-1016 (PDF 66K)

In Impact assessments, Transparency | Tagged

Comments are closed.